A Phase III Double-Blind Trial For Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo For Patients With Tumors Harboring The Anaplastic Lymphoma Kinase (Alk) Fusion Protein
Posted Date: Jan 4, 2018
- Investigator: John Morris
- Specialties: Thoracic Surgery, Hematology/Oncology, Oncology, Cancer, Lung Cancer, Cancer, Radiation Oncology
- Type of Study: Drug
The purpose of this research is to compare any good and bad effects of using the study drug, crizotinib after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. The addition of crizotinib may help prevent the cancer from returning, but it could also cause side effects. The study will allow researchers to know whether this different approach is better, the same or worse than the usual approach.
To Be Eligible To Participate, Patients Must Have Alk-Positive Non-Small Cell Lung Cancer Which Has Been Removed By A Surgeon.
Early Stage, Nsclc, Cancer, Non-Small Cell Lung Cancer, E4512
For More Information:
Uc Cancer Institute